Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The stock

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Nov 08, 2023 11:06am

300 Views

Post# 35723661

The stock

has been bid up over doubled in about 2 weeks, a sell off will happen soon. maybe on news this week or with the financials report next week, because we no P2 start date is a long ways away, investors do not have patience and will take profit and will get back in later. i myself have trimmed about 12k so far, my finger is getting real itcy lol
glta

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec